Loading patent…
AssigneeAcceleron Pharma Inc.
InventorsRajasekhar Naga Venkata Sai Suragani, Patrick Andre
Estimating the term…
In certain aspects, the present disclosure relates to methods of treating chronic liver disease, portal hypertension, primary sclerosing cholangitis, and hepatopulmonary syndrome, particularly associated clinical complications such as, for example, pulmonary fibrosis and/or interstitial lung disease (ILD), methods comprising administering TβRII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides methods for treating one or more complications associated with chronic liver disease, including interstitial lung disease (ILD) and pulmonary fibrosis, with TβRII antagonists of the present disclosure.
A method for treating hepatopulmonary syndrome (HPS), comprising administering to a subject in need thereof a transforming growth factor β receptor II (TβRII) antagonist.
4-13. (canceled)
A method for treating chronic liver disease, comprising administering to a subject in need thereof a transforming growth factor β receptor II (TβRII) antagonist.
(canceled)
A method for treating one or more complications of chronic liver disease, comprising administering to a subject in need thereof a transforming growth factor β receptor II (TβRII) antagonist, wherein the one or more complications of chronic liver disease is selected from the group consisting of spider nevi (spider angiomata, spider angiomas, or nevi araneus), hyperdynamic circulation, clubbing of the fingers or toes, hypertrophic osteoarthropathy, orthodeoxia, cyanosis weakness, fatigue, anorexia, gastrointestinal bleeding, inability to concentrate, menstrual irregularities, decreased libido, skin fragility, bruising, pruritus, ascites, anasarca, nail changes, splenomegaly, a large or small liver, caput medusae, gynecomastia, palmar erythema, testicular atrophy, and/or jaundice.
20-132. (canceled)
134-141. (canceled)
144-161. (canceled)
163-170. (canceled)
Dependencies are inferred from the claim text.